View More Recent Stories
-
Bristol-Myers Squibb (BMY): EMA Validates Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $53 at TD Cowen
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at Goldman Sachs
-
Barclays Downgrades Bristol-Myers Squibb Co. (BMY) to Underweight
-
Midday movers: Bristol-Myers, 3M and Deckers rise; Dexcom falls
-
Bristol-Myers Squibb (BMY) stock gains after raising full-year guidance
-
Bristol-Myers Squibb (BMY) Tops Q2 EPS by 43c, provides guidance
-
Bristol-Myers Squibb (BMY) call put ratio 1.6 calls to 1 put into quarter results
-
Bristol-Myers Squibb (BMY) July 26 weekly 44.5 straddle into quarter results
-
Bristol-Myers Squibb (BMY) July 26 weekly 44.5 straddle priced into quarter results
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $45 at Deutsche Bank
-
10 policies if Trump wins and stock implications: Jefferies
-
Bristol-Myers Squibb (BMY) Receives EMA Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
-
Bristol Myers Squibb Reaches Major Milestone in Environmental Sustainability
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $43 at UBS
-
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America
-
Bristol-Myers Squibb (BMY) Announces U.S. FDA Accelerated Approval of KRAZATI in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic
-
Bristol-Myers Squibb (BMY) Receives EMA Validation of Application for Subcutaneous Nivolumab
-
Bristol-Myers Squibb (BMY) Appoints Michael R. McMullen to its Board
-
Bristol-Myers Squibb (BMY) Declares $0.60 Quarterly Dividend; 5.9% Yield
-
Bristol-Myers Squibb (BMY) Announces FDA Granted Accelerated Approval of Augtyro
-
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
-
Democratic lawmaker presses antitrust enforcers on company ties, settlements
